Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2000037995Phase 4Recruiting
Phase 4, open-label, single-arm trial of pyrotinib in breast cancer and brain metastases, sponsored by Shandong Cancer Hospital. Primary endpoints: Progression Free Survival and Adverse Events. Started Sep 2020; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2000037995.